Valuation under review.
AgomAb Therapeutics is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory conditions with limited treatment options. The company's pipeline centers on two clinical-stage candidates targeting validated pathways: ontunisertib, an oral gastrointestinal-restricted inhibitor of the TGFβ pathway for fibrostenosing Crohn's disease, and AGMB-447, an inhaled ALK5 inhibitor for idiopathic pulmonary fibrosis, along with a preclinical HGF-mimetic monoclonal antibody for liver cirrhosis. AgomAb targets large patient populations with significant unmet medical needs, particularly in fibrotic diseases where current standard-of-care therapies provide only modest efficacy or fail to address underlying fibrosis, positioning the company to build a fully integrated biopharmaceutical enterprise focused on fibrotic disease treatment.
Financial summary not available yet.